Idarucizumab for dabigatran reversal in daily clinical practice: A case series.

Background: Real-life experience with idarucizumab, which reverses the anticoagulant effect of dabigatran, is currently limited.

Objective: To evaluate efficacy and safety of the clinical use of idarucizumab after its availability in Slovenia.

Methods: We analysed consecutive cases treated with idarucizumab in Slovenia from January to October 2016.

[Viral hepatitis B and C in users of psychotropic preparations parenterally administered].

The dynamic study of 198 patients having virus hepatitides B and C was carried out. The etiological diagnosis in these patients had been made on the basis of serological investigation and the determination of markers with the use of the polymerase chain reaction. The manifestations of the disease were compared in 98 drug addicts and 100 patients stating they used no drugs.